Patheon

From Wikipedia, the free encyclopedia

 This article or section needs sources or references that appear in reliable, third-party publications.
Primary sources and sources affiliated with the subject of the article are generally not sufficient for a Wikipedia article. Please include more appropriate citations from reliable sources, or discuss the issue on the talk page.
This article has been tagged since March 2008.
This article or section includes a list of references or external links, but its sources remain unclear because it lacks in-text citations.
You can improve this article by introducing more precise citations.
This article or section needs to be wikified to meet Wikipedia's quality standards.
Please help improve this article with relevant internal links. (March 2008)

Patheon Inc. (commonly known as Patheon) is a contract pharmaceutical company, based in Ontario, Canada. The company undertakes development, manufacturing and packaging of pharmaceutical products, both prescription (Rx) and over the counter (OTC), for a plethora of pharmaceutical, biotechnology and medical device companies, at sites in the USA, Canada, Europe and Puerto Rico.

Patheon's competitors in the contract manufacturing marketplace include Baxter and Cardinal Health, both based in the USA. After the fire to its main plant, Patheon had to relocate to New York, New York.

Contents

[edit] History

Patheon was founded in 1974, then named Custom Pharmaceuticals, in Fort Erie, Canada. It expanded within the Canadian and US markets through aquisitions and mergers, and was listed on the Canadian stock exchange in 1993, when it changed its name to Patheon Inc. It acquired its first European site in Monza (Italy), in 1998, its first US manufacturing site in Cincinnati, Ohio in 2002 and Mova pharmaceuticals, based in Puerto Rico, in 2004. Further to those, Patheon has also acquired sites from numerous other pharmaceutical companies including Roche, Hoechst Marrion Roussell (now Sanofi Aventis) and Novartis, in addition to mergers and company acquisitions.

Although experiencing rapid growth in the decade to 2002, in recent years Patheon, particularly in Europe and Canada has experienced a slowing of growth, resulting in redundacies and reduced operating profit. .

[edit] Sites

Patheon has a total of fourteen sites, including:

[edit] Statistics

Patheon sites have in excess of 3 million square feet of manufacturing space, accommodating approximately 4600 personnel, five hundred of which are involved in pharmaceutical development activities. Patheon manufactures over 700 products for 250 clients distributed to over 150 markets. Operating revenue for 2005 was USD $698 million, 2006 $712 million and 2007 $677 million.

[edit] Dosage Forms, Products

Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate identity being used.

Patheon's clients include many major pharmaceutical brands including Merck & Co, Novartis and Sanofi Aventis, with biotechnology customers including Amgen.

Development activities are undertaken by Patheon Pharmaceutical Development Services (known as PDS), a division of Patheon Inc operating in Europe, Canada and Puerto Rico.

Patheon manufactures products in various dosage forms: oral (tablets, capsules), injectable sterile products (vials, ampoules, pre-filled syringes containing liquids, powders and lyophilisates) and topicals (creams, ointments, drops, nasal sprays, medicated and non-medicated gauze).

[edit] References